Clinical Trials Browser

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Phase 1/2 Active not recruiting

66 enrolled

BreastOther solid neoplasm

HER2-negative Breast Cancer

NCT05693844 2024-05-10

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

15 enrolled

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT05681650 2023-12-12

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

Phase 1/2 Recruiting

30 enrolled

Other solid neoplasm

HER2 Positive Advanced Solid Tumors

NCT05699811 2023-04-28

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

40 enrolled

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT02414945 2023-01-10

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Phase 1/2 Completed

9 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02408016 2021-09-13

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

Phase 1/2 Terminated

11 enrolled 9 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Phase 1/2 Terminated

15 enrolled 14 charts

GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Phase 1/2 Completed

55 enrolled 22 charts

GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms

NCT03171220 2017-06-06

NRT-01

Phase 1/2 Unknown

40 enrolled

Other solid neoplasm

Advanced Malignant Solid Tumor

NCT00002482 2013-11-06

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Phase 1/2 Unknown

Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Clinical Trials

Metro-PD1

A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

DUAL-MESO-NK

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid Tumors

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

NRT-01

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer